Temozolomide-related hematologic toxicity

Claudia Scaringi, Vitaliana De Sanctis, Giuseppe Minniti, Riccardo Maurizi Enrici

Research output: Contribution to journalArticle

Abstract

Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. TMZ is generally well tolerated and safe. The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported. In this review we present an overview of the available literature of HAEs after exposure to TMZ.

Original languageEnglish
Pages (from-to)444-449
Number of pages6
JournalOnkologie
Volume36
Issue number7-8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

temozolomide
Aplastic Anemia
Alkylating Agents
Myelodysplastic Syndromes
Neutropenia
Glioma
Thrombocytopenia
Nausea
Vomiting
Fatigue

Keywords

  • Acute myeloid leukemia
  • Aplastic anemia
  • Glioblastoma
  • Myelodysplastic syndrome
  • Myelosuppression
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Scaringi, C., De Sanctis, V., Minniti, G., & Enrici, R. M. (2013). Temozolomide-related hematologic toxicity. Onkologie, 36(7-8), 444-449. https://doi.org/10.1159/000353752

Temozolomide-related hematologic toxicity. / Scaringi, Claudia; De Sanctis, Vitaliana; Minniti, Giuseppe; Enrici, Riccardo Maurizi.

In: Onkologie, Vol. 36, No. 7-8, 08.2013, p. 444-449.

Research output: Contribution to journalArticle

Scaringi, C, De Sanctis, V, Minniti, G & Enrici, RM 2013, 'Temozolomide-related hematologic toxicity', Onkologie, vol. 36, no. 7-8, pp. 444-449. https://doi.org/10.1159/000353752
Scaringi C, De Sanctis V, Minniti G, Enrici RM. Temozolomide-related hematologic toxicity. Onkologie. 2013 Aug;36(7-8):444-449. https://doi.org/10.1159/000353752
Scaringi, Claudia ; De Sanctis, Vitaliana ; Minniti, Giuseppe ; Enrici, Riccardo Maurizi. / Temozolomide-related hematologic toxicity. In: Onkologie. 2013 ; Vol. 36, No. 7-8. pp. 444-449.
@article{5f7e7e34446d4af1943efa6d6531d2b8,
title = "Temozolomide-related hematologic toxicity",
abstract = "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. TMZ is generally well tolerated and safe. The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported. In this review we present an overview of the available literature of HAEs after exposure to TMZ.",
keywords = "Acute myeloid leukemia, Aplastic anemia, Glioblastoma, Myelodysplastic syndrome, Myelosuppression, Temozolomide",
author = "Claudia Scaringi and {De Sanctis}, Vitaliana and Giuseppe Minniti and Enrici, {Riccardo Maurizi}",
year = "2013",
month = "8",
doi = "10.1159/000353752",
language = "English",
volume = "36",
pages = "444--449",
journal = "Onkologie",
issn = "0378-584X",
publisher = "S. Karger AG",
number = "7-8",

}

TY - JOUR

T1 - Temozolomide-related hematologic toxicity

AU - Scaringi, Claudia

AU - De Sanctis, Vitaliana

AU - Minniti, Giuseppe

AU - Enrici, Riccardo Maurizi

PY - 2013/8

Y1 - 2013/8

N2 - Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. TMZ is generally well tolerated and safe. The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported. In this review we present an overview of the available literature of HAEs after exposure to TMZ.

AB - Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. TMZ is generally well tolerated and safe. The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported. In this review we present an overview of the available literature of HAEs after exposure to TMZ.

KW - Acute myeloid leukemia

KW - Aplastic anemia

KW - Glioblastoma

KW - Myelodysplastic syndrome

KW - Myelosuppression

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84882348438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882348438&partnerID=8YFLogxK

U2 - 10.1159/000353752

DO - 10.1159/000353752

M3 - Article

C2 - 23921765

AN - SCOPUS:84882348438

VL - 36

SP - 444

EP - 449

JO - Onkologie

JF - Onkologie

SN - 0378-584X

IS - 7-8

ER -